Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas.
Seventeen patients less than or equal to 20 years of age with newly diagnosed (n = 10) or recurrent (n = 7) malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) were treated with cyclophosphamide in association with hematopoietic cytokines (GM-CSF or G-CSF). Cyclophosphamide was given at a dose of 2 g/m2 daily for 2 days at 4-week intervals. Toxicity consisted of grade IV neutropenia and thrombocytopenia in 95% and 48% of cycles, respectively. There were no cyclophosphamide-related cardiac, pulmonary, or urothelial toxicities observed. Four of 10 patients with newly diagnosed disease demonstrated responses (three complete and one partial responses; one CR was only of 2 months duration). None of the seven patients with recurrent tumors demonstrated a response. We conclude that high-dose cyclophosphamide warrants further evaluation in children with newly diagnosed malignant glioma.
McCowage
G B
GB
Department of Pediatrics, Hôpital Sainte-Justine, Montreal, Canada.
Friedman
H S
HS
Moghrabi
A
A
Kerby
T
T
Ferrell
L
L
Stewart
E
E
Duncan-Brown
M
M
Fuchs
H E
HE
Tien
R
R
McLendon
R E
RE
Meier
L
L
Kurtzberg
J
J
Ashley
D
D
Colvin
O M
OM
Longee
D C
DC
D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide